About this trial
This prospective randomized controlled trial aims to compare the pharmacokinetic profiles of intraosseous and intravenous tranexamic acid administration in patients undergoing primary total joint arthroplasty. Eligible patients undergoing total hip or total knee arthroplasty will be randomly assigned to receive tranexamic acid either through intraosseous injection or intravenous injection at a dose of 15 mg/kg. Blood samples will be collected at predefined time points to evaluate plasma concentrations and pharmacokinetic characteristics of tranexamic acid. Secondary outcomes include coagulation function, intraoperative blood loss, transfusion rate, and hemoglobin changes. The study aims to provide evidence regarding the pharmacokinetic characteristics and clinical feasibility of intraosseous tranexamic acid administration in joint arthroplasty.
Eligibility criteria
Qualifiers
Age between 18 and 80 years
Patients scheduled for primary total hip arthroplasty or total knee arthroplasty
Diagnosis of osteoarthritis
American Society of Anesthesiologists (ASA) physical status I-III
Disqualifiers
History of coagulation disorders or bleeding disorders
History of pulmonary embolism
Known allergy to tranexamic acid
Pregnancy or breastfeeding
Trial design
Treatments tested in this trial
- Tranexamic Acid
Treatment groups
Sponsors and collaborators
Hua Luo
Lead sponsor
Taizhou Hospital
Sponsor institution